Syncromune®, Inc. Presents Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at Society of Urological Oncology 26th Annual Meeting
Among the 15 patients enrolled in the single-arm Phase 1 trial, 13 (87%) had skeletal metastases at baseline, and following SYNC-T therapy, all bone metastases resolved in seven (54%) of these patients. Responses were durable, with 57% of responders maintaining ongoing remission at the time of analysis. Across the full study cohort SYNC-T achieved an overall response rate (ORR) of 87%, including 53% complete responses (CR) and 33% partial responses (PR). The median response time was 2.9 months, and the median duration of response was 12.1 months. At a median follow-up of 17.2 months, 80% of patients remained alive, suggesting encouraging durability of clinical benefit in this heavily pretreated patient population. Of significance for advanced prostate cancer treatment, the therapy was well tolerated, with most treatment-emergent adverse events (TEAEs) being Grade 1-2 and transient.
Charles Link, M.D., Adjunct Professor at the Lankenau Institute for Medical Research (LIMR) and Co-Founder and Executive Chairman at Syncromune said, “Bone metastases remain a clear unmet clinical challenge in metastatic prostate cancer with few durable responses, despite being present in more than 80% of advanced cases. Data demonstrating complete resolution of bone metastases at the rates we have observed is rare in this population and it reinforces the potential of SYNC-T to elicit a well-tolerated, systemic immune response through an in situ approach. We are encouraged by the trajectory of this program and continue to build on this foundation in our ongoing Phase 2 LEGION-100 trial.”
The open-label, single-arm trial enrolled 15 individuals with histologically verified metastatic prostate cancer who had experienced progression following at least one previous therapy. Patients received SYNC-T SV-102 on a four-week schedule for up to 12 cycles, with clinical assessments performed at 8-week intervals.
Gerald Andriole, M.D., Chief Medical Officer, Urology at Syncromune and presenter of the SUO data, added, “For men with advanced prostate cancer, bone metastases are not only a major driver of pain and disability, but also represent one of the hardest challenges we face as clinicians. Seeing these lesions resolve in a meaningful proportion of patients treated with SYNC-T is very encouraging. Equally important is that SYNC-T was well tolerated in these heavily pre-treated physiologically fragile patients, who often have few remaining options that don’t carry significant toxicity. These findings suggest that in situ immune activation may offer a new path forward for patients who urgently need better and more tolerable therapies.”
Syncromune is enrolling patients for its Phase 2 multicenter trial (LEGION-100, NCT06533644) at sites across the United States, including the Michigan Institute of Urology, the University of Arizona Cancer Center, the University of Pittsburgh Medical Center, the University of Nebraska Medical Center, and Mercy Hospital, St. Louis with additional sites to follow. Please visit www.legion100trial.com to learn more and explore if you or someone you love may qualify.
For more information about Syncromune, please visit www.syncromune.com.
Source: Syncromune®, Inc. (2025). Syncromune®, Inc. Presents Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at Society of Urological Oncology 26th Annual Meeting [Press release]. https://syncromune.com/2025/12/04/syncromune-inc-presents-phase-1-data-highlighting-resolution-of-bone-metastases-in-metastatic-prostate-cancer-patients-at-society-of-urological-oncology-26th-annual-meeting/.